NCCE Japan to use Guardant360 assay as sole liquid biopsy in LC-SCRUM-Japan
Paramount comprehensive liquid biopsy, Guardant360 assay to be utilized as sole liquid biopsy in LC-SCRUM-Japan which is a nationwide genomic screening network run by the National Cancer Center Hospital East Kashiwa , Japan to match metastatic Lung cancer patients with sanctioned drugs and experimental therapies in Clinical Trials.
Guardant Health Co-Founder and CEO Helmy Eltoukhy said “The prevalence of genomic alterations in lung cancer is high in Japan, but tissue samples from lung tumors can be difficult, expensive, and risky to acquire. With a simple blood draw, NCC Japan can more easily test patients and match them with the appropriate drug.”
LC-SCRUM-Japan has been screening patients for targeted therapies in Japan since 2013 using tissue samples for genomic analysis. To date, more than 5,700 genetic screening tests have been performed, and patients identified with genetic alterations have been enrolled in many targeted therapy clinical trials. This new arm is the first to include genomic analysis of blood samples through a comprehensive liquid biopsy.
Koichi Goto, MD, PhD, Chief of the Department of Thoracic Oncology at National Cancer Center Hospital East claimed “I believe introducing Guardant360 into LC-SCRUM-Japan will help make it possible to deliver effective therapeutic agents to more patients and accelerate adoption of personalized medicine in Japan.”